IPCA Laboratories Share Price Today (IPCALAB)
TODAY IN ONE LINE
IPCALAB edged up 0.6% on above-average volume (1.9x avg), in line with Nifty's -0.0% move.
With a market cap of ₹44,350.03 Cr., it trades at a P/E of 39.80. Track live valuations, technical indicators, and peers comparison below. Check delivery conviction and recent filings to build your view.
How good is this company?
Overall performance across 5 key dimensions.
IPCA Laboratories flags & news
Key strengths, potential risks, and recent updates.
Green Flags
- ●Earnings GrowthEPS (TTM) grew by a solid 341.6% YoY
- ●High Capital EfficiencyROCE of 17.3% indicating pricing power
- ●Strong Return on EquityHealthy ROE of 16.0%
- ●Healthy Operating MarginsOPM is structurally strong at 20.5%
- ●Virtually Debt-FreeVery low Debt-to-Equity of 0.00x
- ●Positive Free Cash FlowFCF has been positive for 3 consecutive years
- ●Zero Pledge RiskNo recent active promoter pledging found
Red Flags
No red flags identified
Latest IPCA Laboratories News
What changed recently?
Recent events, corporate actions, and announcements.
IPCA Laboratories Limited valuation: P/E, P/B and sector benchmarks.
Twelve years of multiples investors have paid for IPCA Laboratories Limited, framed against the sector median so the premium or discount is obvious at a glance.
IPCA Laboratories Limited trades at a P/E of 39.80× and P/B of 5.63×, against the Healthcare sector median P/E of 40.97×.
Market-priced ratios use the latest available quote; accounting metrics use the latest reported filing. Compare values with matched peers and the company's own history.
Valuation
Profitability
Growth
Financial Health
IPCA Laboratories Limited technical analysis: indicators, pivots and CPR.
Live RSI, MACD and moving-average signals plus today's pivot and Central Pivot Range levels for IPCA Laboratories Limited — derived from the live tape, not yesterday's close.
IPCA Laboratories Limited last traded at ₹1,789 with an intraday range of ₹1,725–₹1,804.2 — live indicator, pivot and CPR signals below.
Pivot points
Standard pivot — most widely referenced.
Pivot levels · Classic
Live: ₹1789.00| Level | Price (₹) | Distance | % Δ |
|---|---|---|---|
| R4 | 1978.87 | +189.87 | +10.61% |
| R3 | 1899.67 | +110.67 | +6.19% |
| R2 | 1851.93 | +62.93 | +3.52% |
| R1 | 1820.47 | +31.47 | +1.76% |
| PIVOT | 1772.73 | -16.27 | -0.91% |
| CURRENT | 1789.00 | — | — |
| S1 | 1741.27 | -47.73 | -2.67% |
| S2 | 1693.53 | -95.47 | -5.34% |
| S3 | 1662.07 | -126.93 | -7.10% |
| S4 | 1582.87 | -206.13 | -11.52% |
IPCALAB is trading Above CPR, indicating Bullishness
CPR is Wider, suggesting unlikely for trending moves
Day's range: ₹1766.7–₹1790
Trading Inside opening range
IPCA Laboratories Limited financials: P&L, balance sheet, cash flow, ratios.
Reported annual and quarterly results for IPCA Laboratories Limited — consolidated or standalone — with margins, YoY growth and key ratios inline.
IPCA Laboratories Limited reports its full P&L, balance sheet, cash flow and ratios on this page — current market capitalisation of ₹44,350.03 Cr. and reported EPS of ₹44.95.
| Metric | Mar 2025 | Mar 2026 |
|---|---|---|
| Revenue from Operations | 8,940 | 9,646 ▲ 7.9% |
| Sales Growth YoY %Derived | 16.02% | 7.91% |
| Other Income | 93 | 174 ▲ 88.0% |
| Total Income | 9,032 | 9,821 ▲ 8.7% |
| 2,779 | 2,823 ▲ 1.6% | |
| Gross ProfitDerived | 6,161 | 6,824 ▲ 10.8% |
| Gross Margin %Derived | 68.92% | 70.74% |
| 4,435 | 4,845 ▲ 9.2% | |
| EBITDA (Operating Profit)Derived | 1,726 | 1,979 ▲ 14.6% |
| OPM %Derived | 19.31% | 20.51% |
| 278 | 408 ▲ 46.8% | |
| Profit Before Tax (PBT) | 1,131 | 1,573 ▲ 39.0% |
| 344 | 381 ▲ 10.9% | |
| Effective Tax %Derived | 30.38% | 24.24% |
| Total Profit for Period | 785 | 1,184 ▲ 50.8% |
| Less: Non-controlling Interests | 48 | 43 ▼ 10.3% |
| Net Profit (Owner's PAT)Derived | 738 | 1,141 ▲ 54.7% |
| Net Profit Margin %Derived | 8.25% | 11.83% |
| PAT Growth YoY %Derived | 34.77% | 54.69% |
| Earnings Per Share (EPS ₹) | 29.08 | 44.98 ▲ 54.7% |
| Diluted Shares Outstanding (Cr) | 25 | 25 ▲ 0.0% |
| Share of Profit from Associates/JVs | -2 | -8 ▼ 231.4% |
| Other Comprehensive Income (Net of Tax) | -25 | 43 ▲ 274.2% |
| Total Expenses (incl. D&A & Interest) | 7,901 | 8,248 ▲ 4.4% |
| Material Cost % of RevenueDerived | 25.47% | 24.30% |
| Employee Cost % of RevenueDerived | 22.19% | 22.39% |
| Other Cost % of RevenueDerived | 27.42% | 27.83% |
| Interest Coverage (x)Derived | 15.64x | 20.55x |
| Period | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | Trend |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue from Operations | 3,284 | 3,773 ▲ 14.9% | 4,649 ▲ 23.2% | 5,420 ▲ 16.6% | 5,830 ▲ 7.6% | 6,244 ▲ 7.1% | 7,705 ▲ 23.4% | 8,940 ▲ 16.0% | 9,646 ▲ 7.9% | |
| Sales Growth YoY %Derived | — | 14.91% | 23.20% | 16.59% | 7.56% | 7.11% | 23.39% | 16.02% | 7.91% | |
| Other Income | 42 | 58 ▲ 38.0% | 67 ▲ 16.2% | 63 ▼ 6.2% | 67 ▲ 5.9% | 126 ▲ 88.7% | 125 ▼ 0.7% | 93 ▼ 25.6% | 174 ▲ 88.0% | |
| Total Income | 3,325 | 3,831 ▲ 15.2% | 4,716 ▲ 23.1% | 5,483 ▲ 16.3% | 5,896 ▲ 7.5% | 6,370 ▲ 8.0% | 7,830 ▲ 22.9% | 9,032 ▲ 15.4% | 9,821 ▲ 8.7% | |
1,125 | 1,240 ▲ 10.2% | 1,644 ▲ 32.6% | 1,728 ▲ 5.1% | 2,015 ▲ 16.6% | 2,307 ▲ 14.5% | 2,576 ▲ 11.7% | 2,779 ▲ 7.9% | 2,823 ▲ 1.6% | ||
| Gross ProfitDerived | 2,159 | 2,533 ▲ 17.4% | 3,005 ▲ 18.6% | 3,692 ▲ 22.9% | 3,815 ▲ 3.3% | 3,938 ▲ 3.2% | 5,129 ▲ 30.3% | 6,161 ▲ 20.1% | 6,824 ▲ 10.8% | |
| Gross Margin %Derived | 65.74% | 67.14% | 64.63% | 68.11% | 65.44% | 63.06% | 66.57% | 68.92% | 70.74% | |
1,704 | 1,842 ▲ 8.1% | 2,098 ▲ 13.9% | 2,147 ▲ 2.4% | 2,506 ▲ 16.7% | 3,011 ▲ 20.2% | 3,808 ▲ 26.5% | 4,435 ▲ 16.5% | 4,845 ▲ 9.2% | ||
| EBITDA (Operating Profit)Derived | 455 | 692 ▲ 52.2% | 907 ▲ 31.0% | 1,544 ▲ 70.3% | 1,309 ▼ 15.2% | 927 ▼ 29.2% | 1,321 ▲ 42.6% | 1,726 ▲ 30.7% | 1,979 ▲ 14.6% | |
| OPM %Derived | 13.85% | 18.34% | 19.50% | 28.49% | 22.46% | 14.84% | 17.15% | 19.31% | 20.51% | |
202 | 201 ▼ 0.2% | 227 ▲ 12.8% | 218 ▼ 3.9% | 240 ▲ 10.0% | 307 ▲ 27.9% | 388 ▲ 26.3% | 278 ▼ 28.4% | 408 ▲ 46.8% | ||
| Profit Before Tax (PBT) | 295 | 548 ▲ 86.0% | 747 ▲ 36.2% | 1,389 ▲ 86.0% | 1,136 ▼ 18.2% | 745 ▼ 34.4% | 843 ▲ 13.1% | 1,131 ▲ 34.2% | 1,573 ▲ 39.0% | |
51 | 104 ▲ 104.0% | 135 ▲ 29.8% | 240 ▲ 77.4% | 224 ▼ 6.6% | 253 ▲ 13.0% | 313 ▲ 23.7% | 344 ▲ 9.6% | 381 ▲ 10.9% | ||
| Effective Tax %Derived | 17.34% | 19.01% | 18.12% | 17.29% | 19.75% | 33.99% | 37.20% | 30.38% | 24.24% | |
| Total Profit for Period | 239 | 442 ▲ 84.7% | 604 ▲ 36.5% | 1,141 ▲ 89.1% | 890 ▼ 22.0% | 479 ▼ 46.2% | 523 ▲ 9.2% | 785 ▲ 50.2% | 1,184 ▲ 50.8% | |
| Less: Non-controlling Interests | — | -3 | -3 ▼ 5.7% | 1 ▲ 140.9% | 6 ▲ 405.3% | 8 ▲ 34.3% | -24 ▼ 418.5% | 48 ▲ 294.7% | 43 ▼ 10.3% | |
| Net Profit (Owner's PAT)Derived | 239 | 445 ▲ 85.8% | 606 ▲ 36.3% | 1,140 ▲ 88.0% | 884 ▼ 22.4% | 471 ▼ 46.7% | 547 ▲ 16.1% | 738 ▲ 34.8% | 1,141 ▲ 54.7% | |
| Net Profit Margin %Derived | 7.29% | 11.79% | 13.04% | 21.03% | 15.16% | 7.55% | 7.10% | 8.25% | 11.83% | |
| PAT Growth YoY %Derived | — | 85.79% | 36.30% | 88.02% | -22.45% | -46.69% | 16.13% | 34.77% | 54.69% | |
| Earnings Per Share (EPS ₹) | 9.49 | 17.60 ▲ 85.5% | 23.99 ▲ 36.3% | 44.93 ▲ 87.3% | 34.85 ▼ 22.4% | 18.58 ▼ 46.7% | 21.57 ▲ 16.1% | 29.08 ▲ 34.8% | 44.98 ▲ 54.7% | |
| Diluted Shares Outstanding (Cr) | 25 | 25 ▲ 0.1% | 25 ▲ 0.0% | 25 ▲ 0.4% | 25 ▲ 0.0% | 25 ▲ 0.0% | 25 ▲ 0.0% | 25 ▲ 0.0% | 25 ▲ 0.0% | |
| Share of Profit from Associates/JVs | -4 | -2 ▲ 57.2% | -8 ▼ 331.5% | -8 ▲ 1.4% | -21 ▼ 174.8% | -13 ▲ 38.8% | -6 ▲ 51.4% | -2 ▲ 63.6% | -8 ▼ 231.4% | |
| Other Comprehensive Income (Net of Tax) | 9 | -4 ▼ 143.8% | 4 ▲ 192.2% | -0 ▼ 111.3% | 3 ▲ 850.0% | 7 ▲ 144.7% | -9 ▼ 228.7% | -25 ▼ 159.8% | 43 ▲ 274.2% | |
| Total Expenses (incl. D&A & Interest) | 3,031 | 3,283 ▲ 8.3% | 3,969 ▲ 20.9% | 4,094 ▲ 3.1% | 4,761 ▲ 16.3% | 5,625 ▲ 18.1% | 6,987 ▲ 24.2% | 7,901 ▲ 13.1% | 8,248 ▲ 4.4% | |
| Material Cost % of RevenueDerived | 28.40% | 29.31% | 31.41% | 29.47% | 28.55% | 27.36% | 28.76% | 25.47% | 24.30% | |
| Employee Cost % of RevenueDerived | 22.41% | 20.87% | 19.82% | 18.70% | 20.20% | 20.62% | 22.17% | 22.19% | 22.39% | |
| Other Cost % of RevenueDerived | 29.49% | 27.94% | 25.31% | 20.92% | 22.78% | 27.60% | 27.25% | 27.42% | 27.83% | |
| Interest Coverage (x)Derived | 11.53x | 27.00x | 42.19x | 147.70x | 140.03x | 14.61x | 6.97x | 15.64x | 20.55x |
IPCA Laboratories segment analysis : revenue and profit mix.
Disclosed business segments at IPCA Laboratories with their share of revenue and profit, switchable between consolidated and standalone reporting.
IPCA Laboratories discloses revenue and profit across multiple business segments — toggle between consolidated and standalone views to see the mix.
Segment-wise Financial Analysis
The Bull, Bear, and Flip case for IPCA Laboratories Limited.
Our AI distills the core fundamental drivers supporting IPCA Laboratories Limited, the risks that threaten it, and the quantitative conditions that could weaken the thesis.
IPCA Laboratories Limited's investment case rests on 10 positive markers and 10 flagged concerns drawn from the latest reported filings.
What you're getting.
Latest quarterly EPS grew 341.0% YoY, reflecting explosive earnings acceleration and strong operational momentum.
Operating margin of 20.50% latest quarter exceeds peer median, signaling pricing power and cost discipline.
Low debt-to-equity ratio of 0.001x ensures fortress balance sheet with minimal financial leverage risk.
Operating cash flow of ₹780.06 Cr in latest quarter funds growth capex and shareholder distributions sustainably.
Vertically integrated API plus formulation model creates cost advantage versus pure-play generic competitors.
Key Risks.
High P/E of 37.75x trades 24% above peer median, indicating premium valuation with limited margin of safety.
Dividend yield of only 0.34% offers minimal income return, limiting appeal for yield-focused equity investors.
Net profit margin of 11.83% TTM trails peer averages, signaling margin compression concerns despite recent expansion.
ROCE of 17.30% lags peer median of 20%, suggesting suboptimal capital deployment efficiency versus competitors.
FII holdings eased from 10.67% to 10.42%, signals foreign investor caution on valuation and growth sustainability.
Flip Conditions.
Valuation risk. a P/E above 52 (~1.3× the sector multiple of 41.0) would leave less room for earnings disappointment.
Reassess if quarterly profit growth turns negative for two consecutive quarters. The bull case relies on compounding earnings.
Return-quality risk. ROE below 11% would indicate weaker capital compounding.
Income thesis breaks if the dividend is cut or yield falls below 0.17%.
IPCA Laboratories Limited peer comparison — same-sector benchmarks.
Same-sector listed peers ranked on P/E, market cap, dividend yield and growth — IPCA Laboratories Limited is highlighted for quick read-across.
Quick Compare
Peer Comparison
| Company Name |
|---|
IPCA Laboratories Limited chart patterns: breakouts, tops and bottoms.
Auto-detected classical chart patterns for IPCA Laboratories Limited — Double Top/Bottom, Head & Shoulders, Triple Bottom and more — with break levels, targets and quality scores across Intraday, Daily and Weekly timeframes.
- 1Pick how to scan. Detection sets sensitivity — Daily (standard) → Weekly (big swings). History sets how far back to look.
- 2Read the summary. The tiles at the top give the current read: net bias, the strongest pattern, and the one nearest to triggering.
- 3Scan the list. Use the Actionable, Watchlist, and History tabs to browse patterns. Click a pattern card to focus it.
- 4Inspect on the chart. Focusing draws the pattern’s pivots plus its break (blue), target (amber) and invalidation lines.
- 5Filter to what matters. Use the status controls (Confirmed, Forming, Invalidated) to hide noise and find exactly what you are looking for.
Pattern history — every completed pattern and its outcome
IPCA Laboratories Limited delivery volume — last 20 sessions of conviction.
Daily traded volume and delivery percentage for IPCA Laboratories Limited over 20 sessions — the gap between intraday flipping and genuine accumulation.
Latest session delivery in IPCA Laboratories Limited stood at 46.6% of traded volume, against a 20-day average of 53.6%.
IPCA Laboratories announcements: results, concalls, ratings, M&A.
Filings IPCA Laboratories sent to the exchanges, sequenced as they hit the tape — concall transcripts, results, credit ratings and presentations.
IPCA Laboratories files concall transcripts, results, credit ratings and corporate-action notices on the NSE and BSE exchange portals — latest 100 documents below.
Updates
IPCA Laboratories Limited has informed the Exchange regarding ''.Intimation to non-email cases regarding weblink of Annual Report'
Copy of Newspaper Publication
IPCA Laboratories Limited has informed the Exchange about Copy of Newspaper Publication
Record Date
IPCA Laboratories Limited has informed the Exchange that Record date for the purpose of Dividend is 07-Aug-2026.
Shareholders meeting
IPCA Laboratories Limited has informed the Exchange regarding Notice of Annual General Meeting to be held on August 13, 2026
Updates
IPCA Laboratories Limited has informed the Exchange regarding 'Business Responsibility and & Sustainability Report'.
Investor decks & rating reports.
IPCA Laboratories dividend history, splits and bonus issues.
Every dividend, stock split and bonus issue IPCA Laboratories has declared, sequenced by announce and record date.
IPCA Laboratories corporate-action history below covers all declared dividends, stock splits and bonus issues recorded with NSE and BSE.
IPCA Laboratories insider trading: promoter and management activity.
Promoter, director and designated-employee transactions in IPCA Laboratories as reported to SEBI — buying and selling signals from the people who know the business best.
IPCA Laboratories insider activity below tracks 1 reported promoter, director and designated-employee transactions under SEBI Regulation 7(2).
| Insider | Category | Txn Date | Action | Quantity | Value (₹) | Price |
|---|---|---|---|---|---|---|
| Mrs. Usha M. Chandurkar | Insider | 18 Dec 2024 | sell | −40.00 L | ₹599.7 Cr. | ₹1,499.25 |
About IPCA Laboratories Limited: business, sector, key facts.
What IPCA Laboratories Limited does, where it operates, the people running it, and the numbers that describe the entity behind the ticker.
IPCA Laboratories Limited operates in the Pharmaceuticals industry under the Healthcare sector, listed as NSE: IPCALAB, BSE: 524494.
Ipca Laboratories Limited is a multinational pharmaceutical company with a long history, established in 1949 and headquartered in Mumbai, India. The company operates across a broad global footprint, distributing its products to India, Europe, Africa, the Americas, Asia, the CIS region, and Australasia. Their business model is vertically integrated, encompassing both the manufacture and marketing of their products.
A significant portion of Ipca's business involves the production and sale of Active Pharmaceutical Ingredients (APIs). These APIs are key components in the creation of various medications and are provided for a wide range of therapeutic applications. Specifically, Ipca focuses on APIs for anti-hypertensive, anti-malarial, diuretic, DMARD (disease-modifying antirheumatic drug), and anthelmintic treatments. This focus on APIs demonstrates Ipca's commitment to supplying crucial components to the broader pharmaceutical industry.
In addition to APIs, Ipca manufactures and markets a diverse portfolio of both generic and branded pharmaceutical formulations. These formulations cover an extensive range of therapeutic areas, indicating a wide-ranging approach to healthcare needs. These areas include allergy, oncology (anti-neoplastic/cancer drugs), arthritis, epilepsy, cardiology, diabetes, dermatology, gastroenterology, hematology, infectious diseases, neurology, pain management (neuropathic pain and NSAIDs), ophthalmology, orthopedics, psychiatry, respiratory ailments, rheumatology, and urology. Furthermore, they also offer nutraceuticals and probiotics, expanding their reach into complementary health products.
Ipca's global reach is a key component of its business strategy. The company actively exports its products worldwide, showcasing its ability to compete and succeed in international markets. This international focus suggests a commitment to serving global healthcare needs and a capacity to adapt to diverse regulatory and market landscapes. The breadth of its product offerings, from APIs to a wide variety of formulations, positions Ipca to participate in numerous segments of the pharmaceutical market.
Related
Peers, sector trends, screeners and strategy playbooks contextual to this stock.
- Aarey Drugs & Pharmaceuticals (AAREYDRUGS) Share PricePeer
- Aarti Drugs (AARTIDRUGS) Share PricePeer
- Aarti Pharmalabs (AARTIPHARM) Share PricePeer
- Ajanta Pharma (AJANTPHARM) Share PricePeer
- Akums Drugs and Pharmaceuticals (AKUMS) Share PricePeer
- Top Gainers TodayScreener
- EMA Crossover ScreenerScreener
- Stock Quality ScorecardScreener
- Technical DashboardScreener
- Results CalendarScreener
- FII Buying ActivityScreener
- All Technical ScreenersScreener
- All Trading StrategiesStrategy
Questions investors ask about IPCA Laboratories Limited (IPCALAB).
Quick answers grounded in this page's data — price action, fundamentals, ratios and ownership.
01What is the current share price of IPCA Laboratories Limited (IPCALAB)?
The current share price of IPCA Laboratories Limited (IPCALAB) is ₹1,789. Today, the stock has gained by ₹11.40 (0.64%), trading in a range of ₹1,725 to ₹1,804.2. The stock opened at ₹1,790 with a trading volume of 2,38,234 shares.
02Is IPCA Laboratories Limited stock a good investment for long-term?
IPCA Laboratories Limited can be considered for long-term investment based on several factors. The company has a market capitalization of ₹44,350.03 crores, P/E ratio of 39.80, ROE of 16.00%, and ROCE of 17.30%. The dividend yield stands at 0.34%. However, investment decisions should be based on your financial goals, risk appetite, and thorough research. It's recommended to consult with a SEBI-registered financial advisor before making investment decisions.
03What is the 52-week high and low price of IPCA Laboratories Limited stock?
The 52-week high price of IPCA Laboratories Limited (IPCALAB) is ₹1,944.9, while the 52-week low is ₹1,251.6. Currently trading at ₹1,789, the stock is 77.5% away from its 52-week low and 8.0% below its 52-week high. These levels help investors understand the stock's price volatility and trading range over the past year.
04Should I buy IPCA Laboratories Limited stock at the current price?
Whether to buy IPCA Laboratories Limited stock at ₹1,789 depends on multiple factors. The stock is currently trading with a P/E ratio of 39.80 and P/B ratio of 5.63. Today's performance shows a gain of 0.64%. Consider analyzing the company's fundamentals, technical indicators, industry trends, and your investment horizon. Compare these metrics with industry peers and consult a financial advisor for personalized advice.
05What is the dividend yield of IPCA Laboratories Limited and when is the next dividend?
IPCA Laboratories Limited offers a dividend yield of 0.34%, which means for every ₹100 invested at the current price of ₹1,789, you can expect to receive approximately ₹0.34 annually as dividends. The face value of the stock is ₹1.00. For information about the next dividend announcement and ex-dividend date, please check the company's official announcements or visit the BSE/NSE websites.
06What are the key financial ratios and metrics of IPCA Laboratories Limited?
IPCA Laboratories Limited's key financial metrics include: P/E Ratio: 39.80, P/B Ratio: 5.63, ROE: 16.00%, ROCE: 17.30%, Dividend Yield: 0.34%, EPS: ₹44.95, Book Value: ₹317.84, and Debt-to-Equity: 0.10. The company's market cap stands at ₹44,350.03 crores. These metrics help evaluate the company's valuation, profitability, and financial health.
07How is IPCA Laboratories Limited stock performing today in the market?
IPCA Laboratories Limited stock opened at ₹1,790 and is currently trading at ₹1,789, showing a gain of ₹11.40 (0.64%). The intraday high is ₹1,804.2 and low is ₹1,725. The trading volume stands at 2,38,234 shares, indicating moderate market participation today.
08What is the P/E ratio of IPCA Laboratories Limited and what does it indicate?
IPCA Laboratories Limited has a Price-to-Earnings (P/E) ratio of 39.80, which means investors are willing to pay ₹39.80 for every ₹1 of earnings. With an EPS of ₹44.95, this P/E ratio suggests the stock may be trading at a premium, possibly due to high growth expectations. Compare this with industry peers and historical P/E ratios for better context.
The data, ratios and commentary about IPCA Laboratories Limited (IPCALAB) on this page are published for educational and informational purposes only and are not investment, legal or tax advice. StockeZee is not a SEBI-registered investment adviser, research analyst or portfolio manager, and no content here should be construed as a recommendation to buy, hold or sell any security. Live and historical market data may be delayed, revised by the exchanges, or contain errors; figures sourced from third-party feeds and corporate disclosures may not always be current. Past performance is not indicative of future results, and equity investments carry the risk of capital loss. Before acting on anything you read here, please consult a SEBI-registered financial advisor and read all scheme-related documents carefully.